)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
CSPC Innovation Pharmaceutical
CSPC Innovation Pharmaceutical (300765) investor relations material
CSPC Innovation Pharmaceutical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary17 Aug, 2026
Executive summary
Revenue surged 208.72% year-over-year to ¥3.24 billion, driven by biopharma and licensing deals.
Net profit attributable to shareholders reached ¥1.26 billion, reversing a prior loss.
Biopharma segment became the main revenue driver, with major out-licensing to AstraZeneca and Corbus.
R&D investment rose 45.72% year-over-year, supporting a robust pipeline in ADCs, mRNA vaccines, and antibodies.
Financial highlights
Operating cash flow was ¥2.78 billion, up 1,928.74% year-over-year.
Gross margin for biopharma reached 97.22%, with overall gross margin at 77.12%.
Basic and diluted EPS were ¥0.9056, up from a loss per share last year.
Total assets increased 38.75% to ¥8.71 billion; equity attributable to shareholders rose 47.58%.
Non-recurring gains totaled ¥35.25 million, mainly from government grants and fair value changes.
Outlook and guidance
Continued focus on biopharma innovation, with multiple late-stage clinical assets and new launches expected.
Further expansion of global licensing and commercialization partnerships anticipated.
Ongoing investment in R&D and production capacity to support pipeline and market growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CSPC Innovation Pharmaceutical
- Q1 revenue up 40.82% year-over-year, but net loss widened on higher R&D and FX losses.300765
Q1 2026 - Revenue rose but higher R&D and lower margins led to a net loss; biopharma growth was strong.300765Q4 2025
- Revenue up 7.71% but net loss deepens; biopharma focus strengthened by Jushi stake buy.300765Q3 2025
- Revenue up, but net loss driven by R&D surge; biopharma growth and global deals highlight H1.300765Q2 2025
- Revenue and profit fell significantly amid market headwinds and rising R&D costs.300765Q3 2024
- Revenue and profit fell, but expansion into biologics and new drug launches signal future growth.300765Q2 2024
- Net profit plunged 87.63% as R&D spending rose and caffeine prices dropped, but biopharma sales soared 153%.300765Q4 2024
- Revenue fell and losses widened in Q1 2025 amid R&D surge and raw material price drops.300765Q1 2025
Next CSPC Innovation Pharmaceutical earnings date
Q3 202623 Oct, 2026
CSPC Innovation Pharmaceutical
Next CSPC Innovation Pharmaceutical earnings date
Q3 202623 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage